Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × BF-200 ALA × 30 days × Clear all
NCT05662202 2026-05-22

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Biofrontera Inc.

Phase 3 Active not recruiting
172 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡